C-2PZ1telomere extension, modified mRNA, lipid nanoparticles
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Deliver RNA compositions, including potential therapeutic RNA payloads, using lipid nanoparticle formulations.
Compositions and methods for RNA delivery involving LNP-related delivery methods.
PCT patent publication WO2024050372A3 published on 2024-05-16, assigned to Rejuvenation Technologies Inc.
Treat pulmonary fibrosis by extending telomeres in target cells implicated in short-telomere disease biology.
Temporary telomerase activation using modified mRNA, delivered with proprietary lipid nanoparticles for targeted treatment.
Listed by the company as a preclinical Phase I program for pulmonary fibrosis.
Treat chronic liver disease by using telomere extension to address disease mechanisms associated with short telomeres.
Temporary telomerase activation using modified mRNA, delivered with proprietary lipid nanoparticles for targeted treatment.
Listed by the company as a preclinical Phase I program for chronic liver disease.
Treat a hematologic indication through telomere extension in relevant blood or hematopoietic cells.
Temporary telomerase activation using modified mRNA, delivered with proprietary lipid nanoparticles for targeted treatment.
Listed by the company as a preclinical Phase I program for a hematologic indication.
Rewind cellular mechanisms of aging and treat diseases caused by short telomeres through therapeutic telomere extension.
Modified mRNA transiently activates telomerase in specific cells, using proprietary lipid nanoparticle delivery for targeted treatment.
Company reports over $8M in grant funding awarded since 2023 and lists multiple preclinical programs using the platform.
A listed 2015 publication reported that transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells.